Tablets and 116 were randomized to placebo. Treatment was initiated at 36 mg/day and patients continued with incremental increases of 18 mg/day (36 to 108 mg/day) based on meeting specific improvement criteria with acceptable tolerability. At the final study visit, mean change scores (LS Mean, SEM) for the investigator rating on the AISRS demonstrated that Methylphenidate HCl Extended-Release Tablets were statistically significantly superior to placebo.

Study 6 was a multicenter, double-blind, randomized, placebo-controlled, parallel-group, dose-response study (5-week duration) with 3 fixed-dose groups (18, 36, and 72 mg). Patients were randomized to receive Methylphenidate HCl Extended-Release Tablets administered at doses of 18 mg (n=101), 36 mg (n=102), 72 mg/day (n=102), or placebo (n=96). All three doses of Methylphenidate HCl Extended-Release Tablets were statistically significantly more effective than placebo in improving CAARS (Conners' Adult ADHD Rating Scale) total scores at double-blind end point in adult subjects with ADHD.

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING
Methylphenidate HCl Extended-Release Tablets are available in 18 mg, 27 mg, 36 mg, and 54 mg dosage strengths. The 18 mg tablets are yellow and imprinted with "alza 18". The 27 mg tablets are gray and imprinted with "alza 27". The 36 mg tablets are white and imprinted with "alza 36". The 54 mg tablets are brownish-red and imprinted with "alza 54". All four dosage strengths are supplied in bottles containing 100 tablets.

<table>
<thead>
<tr>
<th>Dosage</th>
<th>Bottle Size</th>
<th>NDC Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>18 mg</td>
<td>100-count bottle</td>
<td>NDC 10147-0685-1</td>
</tr>
<tr>
<td>27 mg</td>
<td>100-count bottle</td>
<td>NDC 10147-0688-1</td>
</tr>
<tr>
<td>36 mg</td>
<td>100-count bottle</td>
<td>NDC 10147-0686-1</td>
</tr>
<tr>
<td>54 mg</td>
<td>100-count bottle</td>
<td>NDC 10147-0687-1</td>
</tr>
</tbody>
</table>

Storage and Handling
Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Protect from humidity.

17 PATIENT COUNSELING INFORMATION
See Medication Guide

Priapism
Advise patients, caregivers, and family members of the possibility of painful or prolonged penile erections (priapism). **Instruct the patient to seek immediate medical attention in the event of priapism [see Warnings and Precautions (5.4)].**

Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, including Raynaud's Phenomenon]
Instruct patients beginning treatment with Methylphenidate HCl Extended-Release Tablets about the risk of peripheral vasculopathy, including Raynaud's phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.

Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.